Lupin Limited Total Liabilities
Lupin Limited total liabilities. Based on the latest financial reports, Lupin Limited (LUPIN) has total liabilities worth Rs-225.13 Billion INR (≈ $-2.43 Billion USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Lupin Limited liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Lupin Limited (2004–2026)
Total liabilities of Lupin Limited from 2004 to 2026. This chart illustrates how Lupin Limited's total liabilities have evolved over time, based on quarterly financial data. Explore Lupin Limited (LUPIN) long-term investment share to see how much of total assets are deployed in long-term investments.
Lupin Limited Competitors by Total Liabilities
The table below lists competitors of Lupin Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Boston Properties Inc
NYSE:BXP
|
USA | $17.38 Billion |
|
Bentley Systems Inc
NASDAQ:BSY
|
USA | $2.30 Billion |
|
WISE PLC SPONS.ADR/1
F:6WS0
|
Germany | €17.86 Billion |
|
Moog Inc
NYSE:MOG-A
|
USA | $2.80 Billion |
|
Littelfuse Inc
NASDAQ:LFUS
|
USA | $1.34 Billion |
|
Topbuild Corp
NYSE:BLD
|
USA | $4.31 Billion |
|
Maplebear Inc.
NASDAQ:CART
|
USA | $941.00 Million |
|
American Healthcare REIT, Inc.
NYSE:AHR
|
USA | $2.08 Trillion |
Liability Composition Analysis (2004–2026)
This chart breaks down Lupin Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see how large is Lupin Limited's balance sheet.
Liquidity & Leverage Metrics
Lupin Limited Total Liabilities Ratios Explained
Lupin Limited total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | N/A | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.00 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | N/A | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Lupin Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Lupin Limited (2004–2026)
The table below shows the annual total liabilities of Lupin Limited from 2004 to 2026.
| Year | Total Liabilities | Change |
|---|---|---|
| 2026-03-31 | Rs158.51 Billion ≈ $1.71 Billion |
+33.09% |
| 2025-03-31 | Rs119.11 Billion ≈ $1.29 Billion |
+23.76% |
| 2024-03-31 | Rs96.24 Billion ≈ $1.04 Billion |
-7.58% |
| 2023-03-31 | Rs104.13 Billion ≈ $1.13 Billion |
+8.48% |
| 2022-03-31 | Rs95.99 Billion ≈ $1.04 Billion |
-1.57% |
| 2021-03-31 | Rs97.52 Billion ≈ $1.05 Billion |
-21.37% |
| 2020-03-31 | Rs124.03 Billion ≈ $1.34 Billion |
-12.41% |
| 2019-03-31 | Rs141.60 Billion ≈ $1.53 Billion |
+11.60% |
| 2018-03-31 | Rs126.88 Billion ≈ $1.37 Billion |
-2.96% |
| 2017-03-31 | Rs130.75 Billion ≈ $1.41 Billion |
+14.40% |
| 2016-03-31 | Rs114.29 Billion ≈ $1.24 Billion |
+169.59% |
| 2015-03-31 | Rs42.40 Billion ≈ $458.49 Million |
+32.18% |
| 2014-03-31 | Rs32.08 Billion ≈ $346.88 Million |
-12.13% |
| 2013-03-31 | Rs36.50 Billion ≈ $394.76 Million |
-6.33% |
| 2012-03-31 | Rs38.97 Billion ≈ $421.45 Million |
+39.59% |
| 2011-03-31 | Rs27.92 Billion ≈ $301.92 Million |
+12.02% |
| 2010-03-31 | Rs24.92 Billion ≈ $269.52 Million |
-7.53% |
| 2009-03-31 | Rs26.95 Billion ≈ $291.46 Million |
+29.90% |
| 2008-03-31 | Rs20.75 Billion ≈ $224.37 Million |
+49.29% |
| 2007-03-31 | Rs13.90 Billion ≈ $150.29 Million |
-2.06% |
| 2006-03-31 | Rs14.19 Billion ≈ $153.45 Million |
+64.28% |
| 2005-03-31 | Rs8.64 Billion ≈ $93.40 Million |
+8.17% |
| 2004-03-31 | Rs7.98 Billion ≈ $86.35 Million |
-- |
About Lupin Limited
Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India, the United States, and internationally. The company operates in two segments: Pharmaceuticals and Others. It produces, develops, and markets various branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs). The company also offers products in the therapeutic … Read more